The Drug Discovery Research Team composed of faculties and researchers from Graduate Institute of Cancer Biology and Drug Discovery, College of Pharmacy, and TMU Biomedical Commercialization Center. We focused on molecular design ranging from drug discovery to pre-clinical and clinical stage for both small molecules and biologics.
Lead by Prof. Shiow-Lin Pan from Cancer Biology and Drug Discovery program. In collaboration with Associate Professors Wei-Chun HuangFu and Kai-Cheng Hsu (Graduate Institute of Cancer Biology and Drug Discovery), and Assistant Investigator Han-Li Huang (TMU Biomedical Commercialization Center) for drug discovery targeting cancers and neurodegenerative diseases.
Our research team has two candidate drugs entered preclinical stages. One is a small molecule inhibitor targeting E3 ubiquitin ligase against cancer from Prof. Yun-Yen. This project has been funded by MOST industry-academia cooperation project for 70 million NTD and Taiwan Reputed University Startups to Taiwan Unicorns Program for 35 million NTD. The other is a small molecule HDAC6 inhibitor targeting cancer lead by Prof. Shiow-Lin Pan. This project has been funded by Ministry of Health and Welfare for 36 million NTD and MOST Germination project for 30 million NTD. This drug candidate is expected to file IND and enter phase 1 clinical trial in 2022.
The pan-HDAC inhibitor, MPT0E028, developed by our research team has filed US and Taiwan FDA IND and completed phase 1 clinical trial in 2019. MPT0E028 is expected to enter phase 2 clinical trial in 2021.